Physician profile
Stephen Goodman
NPI 1154325744
$4,422.57
in general payments reported to CMS, 2019-2025
28 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $113 · 2021: $201 · 2022: $634 · 2023: $1,097 · 2024: $813 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,035.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,478.63 | 2019-2025 | |
| Gilead Sciences, INC. | $738.96 | 2019-2025 | Epclusa |
| Janssen Biotech, INC. | $477.05 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $266.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.92 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ferring Pharmaceuticals INC. | $194.13 | 2023-2025 | Rebyota, Clenpiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.49 | 2023-2025 | Xifaxan |
| Medtronic, INC. | $138.35 | 2023 | Interstim |
| Madrigal Pharmaceuticals | $91.91 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $64.76 | 2019-2025 | |
| Celgene Corporation | $62.22 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $58.96 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $54.15 | 2025 | Suflave, Sutab |
| Novo Nordisk INC | $50.07 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.83 | 2023 | Cyltezo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.80 | 2025 | Omvoh |
| Capsovision, INC. | $38.54 | 2023-2025 | Capsocam Plus |
| Qol Medical, LLC | $32.51 | 2019-2020 | |
| Amgen INC. | $24.61 | 2025 | Uplizna |
| Blueprint Medicines Corporation | $23.49 | 2024 | |
| Mallinckrodt Hospital Products INC. | $23.25 | 2023 | Terlivaz |
| Ardelyx, INC. | $21.45 | 2023 | Ibsrela |
| Azurity Pharmaceuticals, INC. | $19.72 | 2025 | Sutab |
| Biocon Biologics INC | $19.71 | 2025 | Yesintek |
| Micro-Tech Endoscopy USA, INC. | $19.05 | 2019 | |
| Celltrion USA INC. | $17.69 | 2024 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $13.04 | 2021 | |
| Merck Sharp & Dohme LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.